Abstract: In one aspect, a method of guarding an automated software includes generating, by a first language model, a training set of rule-violating data, generating, by the first language model, a training set of contrastive examples by altering the rule-violating data into non-violating data, training a guardrail machine learning model using the generated training sets, generating, with an automated software, an output based on a user input, monitoring with the trained guardrail machine learn model whether the generated output violates a rule, and preventing the automated software from transmitting to the user the generated output that violates a rule.

Abstract: In one aspect, a method of guarding an automated software includes generating, by a first language model, a training set of rule-violating data, generating, by the first language model, a training set of contrastive examples by altering the rule-violating data into non-violating data, training a guardrail machine learning model using the generated training sets, generating, with an automated software, an output based on a user input, monitoring with the trained guardrail machine learn model whether the generated output violates a rule, and preventing the automated software from transmitting to the user the generated output that violates a rule.

Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient; and one or more additional therapeutic agents optionally selected from the group consisting of bendamustine, rituximah, and ofatumumab.

Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient; and one or more additional therapeutic agents optionally selected from the group consisting of bendamustine, rituximab, and ofatumumab.

Abstract: A method for detecting a target analyte associated with nano-sized gold- and/or silver-containing detecting labels in a microarray of samples. The labels indicate presence or absence of a target analyte in a sample. The method includes sequentially illuminating at least two sample groups with at least two different monochromatic light beams. The sample groups include (a) a first sample group containing at least one sample potentially containing the target analyte, and (b) a second sample group serving as positive control or negative control. The method also includes (ii) detecting intensity of light reflected, absorbed, or emitted from each of the sample groups when illuminated with each of the monochromatic light beams. (iii) recording groups of values associated with the intensity reflected, absorbed, or emitted light. (iv) comparing the groups of values associated with the sample groups; and (v) determining the presence of the target analyte based on the comparison.

Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient; and one or more additional therapeutic agents optionally selected from the group consisting of bendamustine, rituximab, and ofatumumab.

Abstract: A method for detecting a target analyte associated with nano-sized gold- and/or silver-containing detecting labels in a microarray of samples. The labels indicate presence or absence of a target analyte in a sample. The method includes sequentially illuminating at least two sample groups with at least two different monochromatic light beams. The sample groups include (a) a first sample group containing at least one sample potentially containing the target analyte, and (b) a second sample group serving as positive control or negative control. The method also includes (ii) detecting intensity of light reflected, absorbed, or emitted from each of the sample groups when illuminated with each of the monochromatic light beams. (iii) recording groups of values associated with the intensity reflected, absorbed, or emitted light. (iv) comparing the groups of values associated with the sample groups; and (v) determining the presence of the target analyte based on the comparison.